190 related articles for article (PubMed ID: 7098379)
1. [Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl)].
Musch E; Eichelbaum M; Wang JK; von Sassen W; Castro-Parra M; Dengler HJ
Klin Wochenschr; 1982 May; 60(10):513-9. PubMed ID: 7098379
[TBL] [Abstract][Full Text] [Related]
2. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.
Grönhagen-Riska C; Hellstrom PE; Fröseth B
Am Rev Respir Dis; 1978 Sep; 118(3):461-6. PubMed ID: 707874
[TBL] [Abstract][Full Text] [Related]
3. [Hepatotoxic side-effects of rifampicin; a comparative clinical study (author's transl)].
Kuntz HD; Rausch V
Prax Klin Pneumol; 1977 Nov; 31(11):925-32. PubMed ID: 928291
[No Abstract] [Full Text] [Related]
4. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
Long MW; Snider DE; Farer LS
Am Rev Respir Dis; 1979 Jun; 119(6):879-94. PubMed ID: 110184
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
[TBL] [Abstract][Full Text] [Related]
6. Tuberculosis treated with rifampicin, ethambutol and isoniazid: Danish tuberculosis trial 1972-1974.
Engbaek HC; Heckscher T; Højgaard C; Larsen SO; Rasmussen KN; Vergmann B
Eur J Respir Dis; 1982 Mar; 63(2):84-93. PubMed ID: 7040100
[TBL] [Abstract][Full Text] [Related]
7. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.
Ohno M; Yamaguchi I; Yamamoto I; Fukuda T; Yokota S; Maekura R; Ito M; Yamamoto Y; Ogura T; Maeda K; Komuta K; Igarashi T; Azuma J
Int J Tuberc Lung Dis; 2000 Mar; 4(3):256-61. PubMed ID: 10751073
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxic reactions in children with severe tuberculosis treated with isoniazid-rifampin.
Tsagaropoulou-Stinga H; Mataki-Emmanouilidou T; Karida-Kavalioti S; Manios S
Pediatr Infect Dis; 1985; 4(3):270-3. PubMed ID: 4000989
[TBL] [Abstract][Full Text] [Related]
9. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis.
Gurumurthy P; Krishnamurthy MS; Nazareth O; Parthasarathy R; Sarma GR; Somasundaram PR; Tripathy SP; Ellard GA
Am Rev Respir Dis; 1984 Jan; 129(1):58-61. PubMed ID: 6367570
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
[TBL] [Abstract][Full Text] [Related]
11. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
Ellard GA
Rev Mal Respir; 1984; 1(4):207-19. PubMed ID: 6505358
[TBL] [Abstract][Full Text] [Related]
12. [Halothane and antituberculous drugs--a hepatotoxic combination? (author's transl)].
Schmidt-Wilcke HA; Wolfert W; Grundmann E
Z Gastroenterol; 1977 Aug; 15(8):504-11. PubMed ID: 906600
[TBL] [Abstract][Full Text] [Related]
13. Ethambutol compared to rifampin in original treatment of pulmonary tuberculosis.
Bobrowitz ID
Lung; 1980; 157(3):117-25. PubMed ID: 7382540
[No Abstract] [Full Text] [Related]
14. Hepatic dysfunction in undernourished patients receiving isoniazid and rifampicin.
Krishnaswamy K; Prasad CE; Murthy KJ
Trop Geogr Med; 1991; 43(1-2):156-60. PubMed ID: 1750106
[TBL] [Abstract][Full Text] [Related]
15. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
[TBL] [Abstract][Full Text] [Related]
16. [The adverse effects of 2 therapy combinations (SM, PAS, INH, RMP, INH, EMB) in the intensive treatment phase of pulmonary tuberculosis].
Knop P; Kindler U; Merholz T
Med Welt; 1976 Feb; 27(8):389-90. PubMed ID: 1256308
[No Abstract] [Full Text] [Related]
17. [Clinico-pharmacokinetic interactions of rifampicin, pyrazinamide and isoniazide].
Musch E; Loos U; Schwabe HK
Pneumologie; 1990 Feb; 44 Suppl 1():486-7. PubMed ID: 2367444
[TBL] [Abstract][Full Text] [Related]
18. [Simultaneous study of the induction effect of rifampicin and the phenotype for acetylation of isoniazid in 21 patients with tuberculosis undergoing a combination treatment].
Chailleux E; Ordronneau J; Le Normand Y; Kergueris MF; Larousse C
Rev Fr Mal Respir; 1980; 8(3):219-24. PubMed ID: 7187065
[TBL] [Abstract][Full Text] [Related]
19. [Rifampicin in the treatment of active pulmonary tuberculosis. Controlled trial of isoniazid-rifampicin-thiocarlide versus isoniazid-streptomycin-thiocarlide in untreated tuberculosis. Treatment of relapses with the combination rifampicin-ethambutol-thiocarlide].
Chioléro R
Schweiz Med Wochenschr; 1974 Mar; 104(10):356-64. PubMed ID: 4206521
[No Abstract] [Full Text] [Related]
20. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype.
Yamamoto T; Suou T; Hirayama C
Hepatology; 1986; 6(2):295-8. PubMed ID: 3957235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
